Laboratorios Farmaceuticos RoviLABFF 93 3-Year Share Buyback Ratio is 0.80 as of Mar. 2026, which is 300% above its 10-year median of 0.20. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review. Among 645 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 90.08% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Laboratorios Farmaceuticos Rovi's current 3-Year Share Buyback Ratio was 0.80%.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's 3-Year Share Buyback Ratio or its related term are showing as below:
LABFF'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -4 Med: 0.2 Max: 2.3
Current: 0.8
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest 3-Year Share Buyback Ratio was 2.30%. The lowest was -4.00%. And the median was 0.20%.
LABFF's 3-Year Share Buyback Ratio is ranked better than 90.08% of 645
companies
in the Drug Manufacturers industry
Industry Median: -1.9
vs LABFF: 0.80
Laboratorios Farmaceuticos Rovi (OTCPK:LABFF) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Laboratorios Farmaceuticos Rovi 3-Year Share Buyback Ratio Related Terms
LABFF vs ZTS, UTHR, VTRS: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 3-Year Share Buyback Ratio falls into.
Laboratorios Farmaceuticos Rovi 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.80 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a 3-Year Share Buyback Ratio of 0.80 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. This is 300% above median its historical median of 0.20. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #64 out of 645 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Laboratorios Farmaceuticos Rovi's 3-Year Share Buyback Ratio too high?
Laboratorios Farmaceuticos Rovi's current 3-Year Share Buyback Ratio of 0.80 is 300% above median its 10-year median of 0.20. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #64 out of 645 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's 3-Year Share Buyback Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #64 out of 645 companies for 3-Year Share Buyback Ratio. This places Laboratorios Farmaceuticos Rovi in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current 3-Year Share Buyback Ratio is 0.80, which is 300% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current 3-Year Share Buyback Ratio of 0.80. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current 3-Year Share Buyback Ratio is 0.80, which is 300% above median its 10-year median of 0.20. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current 3-Year Share Buyback Ratio is 0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
3-Year Share Buyback Ratio: 0.80 (300% above median its 10-year median of 0.20)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 